The Business Research Company’s Janus Kinase (JAK) Inhibitors Global Market Report 2023 is the most detailed report available on the market, including broad forecast periods and multiple geographies. The report covers the historic period – 2010-2021, and the forecast period – 2023-2032. The Janus Kinase (JAK) Inhibitors Global Market Report 2023 evaluates janus kinase (jak) inhibitors market size, growth rate, drivers, trends, and major companies.
The report provides a global perspective by covering 60 geographies and focusing on major economies in each region – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=12524&type=smp
The global Janus Kinase (JAK) inhibitors market is expected to grow from $14.61 billion in 2022 to $17.29 billion in 2023 at a compound annual growth rate (CAGR) of 18.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The Janus Kinase (JAK) inhibitors market is expected to reach $33.38 billion in 2027 at a CAGR of 17.9%.
The increase in instances of autoimmune diseases is expected to propel the growth of the Janus kinase (JAK) inhibitors market. Autoimmune diseases are a broad group of disorders characterized by an abnormal immune response in which the immune system mistakenly attacks and damages healthy cells, tissues, and organs. Janus Kinase (JAK) inhibitors provide therapeutic benefits for autoimmune diseases by modulating the immune system, reducing inflammation, and alleviating symptoms such as rheumatoid arthritis. For instance, in December 2022, according to the National Psoriasis Foundation, a US-based non-profit organization serving people with Psoriasis and psoriatic arthritis, Psoriasis affected more than 8 million people in America and 125 million individuals worldwide, or 2 to 3% of the population. Furthermore, in September 2022, according to the Centers for Disease Control and Prevention, a US-based national public health agency, Diabetes was diagnosed in 28.7 million people of all ages, or 8.7% of the US population, and 5.7% of all US individuals with confirmed Diabetes—or 1.6 million people aged 20 and older—reported having type 1 diabetes and requiring insulin. Therefore, the increase in instances of autoimmune diseases is driving the growth of the Janus kinase (JAK) inhibitors market.
Get More Information On The Janus Kinase (JAK) Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report
The janus kinase (jak) inhibitors market segments in the report are:
1) By Inhibitors Type: Ruxolitinib, Tofacitinib, Oclacitinib, Baricitinib, Peficitinib, Other Inhibitor Types
2) By Mode Of Administration: Injectable, Oral, Other Modes Of Administration
3) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies
4) By Application: Autoimmune Disorders, Oncology, Inflammatory Disorders, Metabolic Disorders
The table of contents in TBRC’s janus kinase (jak) inhibitors market report includes:
- Executive Summary
- Janus Kinase (JAK) Inhibitors Market Characteristics
- Janus Kinase (JAK) Inhibitors Market Trends And Strategies
- Janus Kinase (JAK) Inhibitors Market – Macro Economic Scenario
- Janus Kinase (JAK) Inhibitors Market Segmentation.
.
.
- Global Janus Kinase (JAK) Inhibitors Market Competitive Benchmarking
- Global Janus Kinase (JAK) Inhibitors Market Competitive Dashboard
- Key Mergers And Acquisitions In The Janus Kinase (JAK) Inhibitors Market
- Janus Kinase (JAK) Inhibitors Market Future Outlook and Potential Analysis
- Appendix
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
